ABSTRACT
CONTEXT: Accumulating data propose that active injecting drug users might not differ from the general population in terms of sustained virological response when adherent to therapy for chronic hepatitis C. However, current guidelines contain restrictive recommendations for therapy in this group of patients. OBJECTIVE: Therefore, we evaluated a cohort of chronic hepatitis C patients regarding the potent influence of active drug using on initial informed consent, compliance and sustained virological response to treatment. METHOD: For that purpose, 162 consecutive patients (of which 62 active injecting drug users), who had been evaluated during the last 6 years in our center for chronic hepatitis C and proposed to receive treatment with pegylated interferon alpha and ribavirin, were enrolled. Initial informed consent, compliance, and sustained virological response as well as data regarding age, gender, body mass index, genotype, viral load, coinfection with HBV/HDV/HIV, administered interferon alpha (2a or 2b), liver function tests, liver histology, urban residence, ethnicity, and concomitant use of alcohol were collected and analyzed in respect with injecting drug using. RESULTS: Injecting drug using was positively correlated with male gender (P<0.001), young age (P<0.001), native origin (P = 0.043), and concomitant use of alcohol (P<0.001). Comparable initial informed consent (P = 0.836), compliance (P = 0.879), and sustained virological response (P = 0.132) were observed between injecting drug users and non- injecting drug users. The results were confirmed using a multiple regression model. CONCLUSION: Our data further support that active injecting drug users do not constitute a distinct chronic hepatitis C patient group in terms of initial informed consent, compliance, or sustained virological response. Therefore, injecting drug using should not be a major determinant influencing the decision for treatment of chronic hepatitis C in eligible patients.
CONTEXTO: Dados acumulados demonstram que usuários ativos de drogas injetáveis podem não diferir da população em geral em termos de resposta virológica sustentada quando aderentes à terapia para a hepatite crônica C. No entanto, as atuais orientações publicadas contêm recomendações restritivas para a terapia nesse grupo de pacientes. OBJETIVO: Com este propósito, avaliou-se uma coorte de pacientes com hepatite crônica C após consentimento informado inicial, no que diz respeito à influência da droga ativa na adesão e na resposta virológica sustentada ao tratamento. MÉTODOS: Para o efeito, foram convidados 162 pacientes (dos quais 62 ativos usuários de drogas injetáveis), que foram avaliados durante os últimos 6 anos em um centro de referência para a hepatite crônica C e se propuseram a receber tratamento com interferon alfa peguilado e ribavirina. O consentimento inicial, a adesão ao tratamento e a resposta virológica sustentada, bem como dados sobre idade, sexo, índice de massa corporal, genótipo, carga viral, com coinfecção HBV/HDV/HIV, tipo de interferon alfa administrado (2a ou 2b), testes de função hepática, histologia hepática, residência urbana, etnia e uso concomitante de álcool foram coletados e analisados em relação com o uso de drogas injetáveis. RESULTADOS: O uso de drogas injetáveis teve correlação positiva com o sexo masculino (P<0,001), idade (P<0,001), de origem nativa (P = 0,043) e uso concomitante de álcool (P<0,001). Foram observados entre usuários de drogas injetáveis e usuários de drogas não-injetáveis dados comparáveis em relação ao consentimento informado inicial (P = 0,836), adesão (P = 0,879) e resposta virológica sustentada (P = 0,132). Os resultados foram confirmados através de um modelo de regressão múltipla. CONCLUSÃO: Os dados confirmam ainda que usuários ativos de drogas injetáveis não constituem um grupo distinto de paciente com hepatite crônica C em termos de consentimento inicial, adesão, ou a resposta virológica sustentada. Assim, o uso de drogas injetáveis não deve ser um dos principais determinantes que influenciam a decisão para o tratamento da hepatite C crônica em pacientes elegíveis.
Subject(s)
Adult , Female , Humans , Male , Middle Aged , Antiviral Agents/therapeutic use , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/virology , Interferon-alpha , Ribavirin/therapeutic use , Substance Abuse, Intravenous/virology , Cohort Studies , Drug Therapy, Combination , Genotype , Hepacivirus/genetics , Medication Adherence , Socioeconomic Factors , Viral LoadABSTRACT
It was observed in the city of Salvador, State of Bahia, the highest seroprevalence of human T cell lymphotropic virus type 1 (HTLV-1) infection in Brazil as demonstrated by national wide blood bank surveys. In this paper, we report results of an investigation of drug use and sexual behavior associated with HTLV-I infection among male and female injecting drug users (IDUs) in Salvador. A cross sectional study was conducted in the Historical District of Salvador from 1994 to 1996 (Projeto Brasil-Salvador) and 216 asymptomatic IDUs were selected using the snowball contact technique. Blood samples were collected for serological assays. Sera were screened for human immunodeficiency virus (HIV-1/2) and HTLV-I/II antibodies by ELISA and confirmed by Western blot. The overall prevalence of HTLV-I/II was 35.2 per cent (76/216). The seroprevalence of HTLV-I, HTLV-II and HIV-1 was for males 22 per cent, 11.3 per cent and 44.1 per cent and for females 46.2 per cent, 10.3 per cent and 74.4 per cent respectively. HTLV-I was identified in 72.4 per cent of HTLV positive IDUs. Variables which were significantly associated with HTLV-I infection among males included needles sharing practices, duration of injecting drug use, HIV-1 seropositivity and syphilis. Among women, duration of injecting drug use and syphilis were strongly associated with HTLV-I infection. Multivariate analysis did not change the direction of these associations. Sexual intercourse might play a more important role in HTLV-I infection among women than in men.
Subject(s)
Male , Female , Substance Abuse, Intravenous/virology , HIV-1 , Human T-lymphotropic virus 1 , Risk Factors , BrazilABSTRACT
In order to assess the molecular epidemiology of HIV-1 in two neighboring cities located near the epicenter of the HIV-1 epidemics in Brazil (Santos and São Paulo), we investigated 83 HIV-1 strains obtained from samples collected in 1995 from intravenous drug users. The V3 through V5 region of the envelope of gp 120 was analyzed by heteroduplex mobility analysis. Of the 95 samples, 12 (12.6 percent) were PCR negative (6 samples from each group); low DNA concentration was the reason for non-amplification in half of these cases. Of the 42 typed cases from São Paulo, 34 (81 percent, 95 percent confidence limits 74.9 to 87.0 percent) were B and 8 (19 percent, 95 percent confidence limits 12.9 to 25.0 percent) were F, whereas of the 41 typed cases from Santos, 39 (95 percent, 95 percent confidence limits 91.6 to 98.4 percent) were B and 2 (5 percent, 95 percent confidence limits 1.6 to 8.4 percent) were C. We therefore confirm the relationship between clade F and intravenous drug use in São Paulo, and the presence of clade C in Santos. The fact that different genetic subtypes of HIV-1 are co-circulating indicates a need for continuous surveillance for these subtypes as well as for recombinant viruses in Brazil
Subject(s)
Humans , Male , Female , Adult , Acquired Immunodeficiency Syndrome/epidemiology , HIV-1/genetics , Substance Abuse, Intravenous/virology , Brazil/epidemiology , Heteroduplex Analysis , HIV-1/classification , HIV-1/isolation & purification , Prevalence , Prospective StudiesABSTRACT
Human Herpes virus type-8 (HHV-8) seroprevalence was studied in a population of HIV positive intravenous drug users (IVDUs) from Argentina. Analysis of this population also indirectly made it possible to study HHV-8 blood transmission, because these individuals frequently engage in needle sharing behavior and are capable of acquiring a broad array of blood borne pathogens, including Hepatitis B/C virus. The seroprevalence of HHV-8 in IVDUs was compared to a group of non-IVDUs and HIV negative individuals. Of the 223 individuals tested, 13.45 percent were HHV-8 positive, 16.99 percent in the IVDUs group, and 5.71 percent in the non-IVDUs. Among HIV positive IVDUs, 25/144 (17.36 percent) were also HHV-8 seropositive. The seropositivity rate of HHV-8 in HIV negative IVDUs was 11.1 percent. In contrast, HHV-8 seroprevalence in HIV negative heterosexual individuals without drug usage behavior was even lower (5.71 percent). The rate of HHV-8 infection in HIV positive IVDUs was three times as high compared to the non IVDU HIV negative individuals, suggesting that IVDU is a risk for HHV-8 infection. Furthermore, it was found that IVDUs showed a very high rate of Hepatitis B/C (52.77 percent), which also correlate with HHV-8 infection in this population (23.68 percent). All Hepatitis B/C positive individuals were also HIV positive. Our data confirm other studies showing that individuals who share needles are at risk for acquiring Hepatitis B/C and HIV infections. In addition, our results suggest that they are also at risk to acquiring HHV-8 infection by the same route.